We interviewed GraniteShares' CEO Will Rhind from New York, soon after they launched a suite of ETP's which allow you to invest in three different baskets of giant US tech stocks. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,313.00
Bid: 2,313.00
Ask: 2,314.00
Change: -24.00 (-1.03%)
Spread: 1.00 (0.04%)
Open: 2,334.00
High: 2,354.00
Low: 2,313.00
Yest. Close: 2,337.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

TOP NEWS: Hikma Pharmaceuticals Hikes Dividend 14% As Earnings Climb

Fri, 7th Aug 2020 08:23

(Alliance News) - Hikma Pharmaceuticals PLC on Friday posted a rise in earnings for the first half of 2020, as it revised its full-year guidance amid a positive outlook.

Shares in the FTSE 100 generic pharmaceuticals maker were trading 8.3% higher at 2,335.20 pence each on Friday morning in London.

Hikma said pretax profit for the six months ended June 30 was USD274 million, up 21% year-on-year from USD226 million. This was as revenue rose 7.6% to USD1.13 billion from USD1.05 billion the year prior. Operating margin was 25%, improved from 24%.

An interim dividend of 16.0 cents was declared, up 14% from 14.0 cents.

Hikma said the improved performance reflected growth in all three of its businesses, highlighting a "particularly strong" performance from its Injectables business.

Revenue from the Injectables business grew 13% to USD485 million, driven by increased demand for Covid-19 related products in the US and EU.

Improved performance of the Generic business was supported by better-than-expected performance from new product launches, with the segment bringing in USD369 million in revenue, up from USD368 million the year prior.

Revenue from the Branded business achieved a strong performance in the company's tier one Middle East and North Africa market, recording 14% growth to GBP275 million.

Looking ahead, Hikma revised it guidance for the full year. It now expects Injectables revenue to be between USD950 million to USD980 million, up from USD894 million in 2019. Core operating margin is expected to be in the range of 38% to 40%, up from previous forecasts of 35% and 37%.

Generics revenue is now expected to be in the range of USD720 million to USD760 million, exceeding April's forecasts of between USD700 million to USD750 million. Generics revenue in 2019 was USD719 million. Core operating margin is forecast to be around 21%, up from previous forecasts of between 16% and 18%.

Branded revenue expected to grow in the mid-single digits.

"We have delivered strong first-half results, which are ahead of our initial expectations and reflect good progress in each of our three businesses. Our performance demonstrates the breadth and resilience of our portfolio, as well as the vital role of the generic medicines we supply. We have a positive outlook for each of our three businesses and look forward to the second half with confidence," said Chief Executive Siggi Olafsson.

As at the end of June, Hikma had cash of USD413 million.

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Today 09:46

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

30 Apr 21 17:01

TOP NEWS: Hikma Pharma confident after promising start to year

TOP NEWS: Hikma Pharma confident after promising start to year

30 Apr 21 08:58

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

30 Apr 21 07:57

Hikma predicts generics revenue at top of guidance

(Sharecast News) - Hikma Pharmaceutical said it made a good start to 2021 and that annual revenue from generic treatments would be at the top of guidance.

30 Apr 21 07:38

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

23 Apr 21 16:01

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

21 Apr 21 12:08

Hikma resumes asthma drug launch, Vectura pays special dividend

Hikma resumes asthma drug launch, Vectura pays special dividend

21 Apr 21 10:06

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

21 Apr 21 09:01

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

21 Apr 21 07:52

Hikma resumes US launch of 'Advair Diskus' generic

(Sharecast News) - Hikma Pharmaceuticals has resumed the launch of its generic version of GlaxoSmithKline's 'Advair Diskus' in the United States, it announced on Wednesday, following Food and Drug Administration (FDA) approval of an amendment it submitted to its Abbreviated New Drug Application in January.

21 Apr 21 07:30

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

19 Apr 21 16:02

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

16 Apr 21 14:54

LONDON MARKET CLOSE: Stocks end lower; investors shun Deliveroo

LONDON MARKET CLOSE: Stocks end lower; investors shun Deliveroo

31 Mar 21 17:04

Wednesday broker round-up

(Sharecast News) - Hikma: Jefferies upgrades to buy with a target price of 2,870p.

31 Mar 21 13:40

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.